Mirum Pharmaceuticals Inc (08D)

Currency in EUR
45.00
+0.20(+0.45%)
Closed·
Unusual trading volume
Fair Value
Day's Range
45.0045.60
52 wk Range
31.8052.50
Key Statistics
Bid/Ask
43.80 / 45.80
Prev. Close
44.8
Open
45.6
Day's Range
45-45.6
52 wk Range
31.8-52.5
Volume
278
Average Volume (3m)
96
1-Year Change
15.98%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
08D Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Mirum Pharmaceuticals Inc Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Compare 08D to Peers and Sector

Metrics to compare
08D
Peers
Sector
Relationship
P/E Ratio
0.0x−4.3x−0.5x
PEG Ratio
0.00−0.180.00
Price/Book
0.0x2.6x2.6x
Price / LTM Sales
0.0x11.3x3.3x
Upside (Analyst Target)
0.0%110.5%42.4%
Fair Value Upside
Unlock25.0%7.2%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

08D Income Statement

People Also Watch

116.01
CRDO
+6.06%
128.87
ALAB
+8.83%
58.88
NXT
-9.28%
50.510
SMR
+3.14%
129.46
BPMC
+0.14%

FAQ

What Stock Exchange Does Mirum Pharmaceuticals Inc Trade On?

Mirum Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Mirum Pharmaceuticals Inc?

The stock symbol for Mirum Pharmaceuticals Inc is "08D."

What Is the Mirum Pharmaceuticals Inc Market Cap?

As of today, Mirum Pharmaceuticals Inc market cap is 2.22B.

What Is Mirum Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Mirum Pharmaceuticals Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 08D a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Mirum Pharmaceuticals Inc Stock Split?

Mirum Pharmaceuticals Inc has split 0 times.

What is the current trading status of Mirum Pharmaceuticals Inc (08D)?

As of 31 Jul 2025, Mirum Pharmaceuticals Inc (08D) is trading at a price of 45.00, with a previous close of 44.80. The stock has fluctuated within a day range of 45.00 to 45.60, while its 52-week range spans from 31.80 to 52.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.